Skip to main content

Advertisement

Fig. 5 | BMC Cancer

Fig. 5

From: Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method

Fig. 5

Hypothetical model of EGFR and ANXA3 to fluoropyrimidine resistance in fluoropyrimidine-treated gastric cancer patients. ANXA3 overexpression confers resistance tyrosine kinase inhibitors targeting ERBB/RAS pathway. High expression of DPD is associated with mutations in EGFR. DPD is an inactivating and rate-limiting enzyme for fluoropyrimidine

Back to article page